To include your compound in the COVID-19 Resource Center, submit it here.

PharmaMar's Zepsyre misses in first Phase III trial

PharmaMar S.A. (Madrid:PHM) lost €0.88 (34%) to €1.70 on Friday after reporting that Zepsyre lurbinectedin

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE